JP5934647B2 - クロストリジウム・ディフィシル感染症のための選択的抗菌薬 - Google Patents

クロストリジウム・ディフィシル感染症のための選択的抗菌薬 Download PDF

Info

Publication number
JP5934647B2
JP5934647B2 JP2012528919A JP2012528919A JP5934647B2 JP 5934647 B2 JP5934647 B2 JP 5934647B2 JP 2012528919 A JP2012528919 A JP 2012528919A JP 2012528919 A JP2012528919 A JP 2012528919A JP 5934647 B2 JP5934647 B2 JP 5934647B2
Authority
JP
Japan
Prior art keywords
morpholinyl
oxopurine
dichlorobenzylamino
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012528919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504592A (ja
JP2013504592A5 (enExample
Inventor
ライト，ジョージ，イー．
シュー，ウェイ−チュー
Original Assignee
グルシンシーシス インコーポレーテッド
グルシンシーシス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グルシンシーシス インコーポレーテッド, グルシンシーシス インコーポレーテッド filed Critical グルシンシーシス インコーポレーテッド
Publication of JP2013504592A publication Critical patent/JP2013504592A/ja
Publication of JP2013504592A5 publication Critical patent/JP2013504592A5/ja
Application granted granted Critical
Publication of JP5934647B2 publication Critical patent/JP5934647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012528919A 2009-09-11 2010-09-10 クロストリジウム・ディフィシル感染症のための選択的抗菌薬 Active JP5934647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27643609P 2009-09-11 2009-09-11
US61/276,436 2009-09-11
PCT/US2010/048379 WO2011031935A1 (en) 2009-09-11 2010-09-10 Selective antibacterials for clostridium difficile infections

Publications (3)

Publication Number Publication Date
JP2013504592A JP2013504592A (ja) 2013-02-07
JP2013504592A5 JP2013504592A5 (enExample) 2013-10-31
JP5934647B2 true JP5934647B2 (ja) 2016-06-15

Family

ID=43732808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528919A Active JP5934647B2 (ja) 2009-09-11 2010-09-10 クロストリジウム・ディフィシル感染症のための選択的抗菌薬

Country Status (5)

Country Link
US (1) US8796292B2 (enExample)
EP (1) EP2475252B1 (enExample)
JP (1) JP5934647B2 (enExample)
CA (1) CA2772907C (enExample)
WO (1) WO2011031935A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10723741B1 (en) * 2018-12-21 2020-07-28 Acurx Pharmaceuticals, Llc DNA polymerase IIIC inhibitors and use thereof
JP2024522813A (ja) * 2021-06-16 2024-06-21 アクルクス ファーマシューティカルズ、インコーポレイテッド マイクロバイオームの健康を促進するためのイベザポルスタットの使用
CN120202009A (zh) * 2022-10-17 2025-06-24 阿科利斯制药股份有限公司 用于改善健康的化合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
AU2247701A (en) 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
WO2001028561A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
WO2001029045A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
EP1401829B1 (en) 2001-06-15 2012-08-22 Microbiotix, Inc. Novel heterocyclic antibacterial compounds
US6777420B2 (en) 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
CA2473724A1 (en) * 2002-02-08 2003-08-14 Glsynthesis Inc. Purine and isosteric antibacterial compounds
AU2003240545A1 (en) * 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
AU2003303953B2 (en) * 2002-09-10 2007-10-04 Microbiotix, Inc. Antibacterial pyrazole carboxylic acid hydrazides
FR2906244B1 (fr) * 2006-09-22 2010-09-10 Centre Nat Rech Scient Nouvelle classe de composes derives de terpene a activite antibiotique, compositions les contenant et utilisations.

Also Published As

Publication number Publication date
US20120232077A1 (en) 2012-09-13
EP2475252A4 (en) 2013-07-10
WO2011031935A1 (en) 2011-03-17
CA2772907A1 (en) 2011-03-17
JP2013504592A (ja) 2013-02-07
US8796292B2 (en) 2014-08-05
EP2475252B1 (en) 2016-11-16
EP2475252A1 (en) 2012-07-18
CA2772907C (en) 2018-01-09

Similar Documents

Publication Publication Date Title
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
AU2022256175B2 (en) Antimicrobial compounds, compositions, and uses thereof
KR20140029554A (ko) 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제
EA020733B1 (ru) Производные актагардина
US20060148730A1 (en) Method of treating tuberculosis
JP5934647B2 (ja) クロストリジウム・ディフィシル感染症のための選択的抗菌薬
CA2601202C (en) New hybrid oligomers, their preparation process and pharmaceutical compositions containing them
RU2745985C1 (ru) Антикоронавирусный терапевтический агент - замещенный 7-гидрокси-3,4,12,12а-тетрагидро-1H-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион для профилактики и лечения COVID-19
US6822098B2 (en) Ester or amide derivatives
US20220024925A1 (en) Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof
US8247400B2 (en) Cephem compounds useful for the treatment of bacterial infections
CN104892600B (zh) 7‑（3‑氨甲基‑4‑取代苄氧亚胺基‑1‑吡咯烷基）萘啶酮羧酸类化合物
CN101863876A (zh) 有7-(3-氨基-4-肟基)-1-哌啶基取代基的氟喹诺酮及其组合物的应用
CN108440446A (zh) 含有肟基片段的苯并噻嗪-4-酮类化合物及其制备方法
HK40060969B (zh) 抗微生物化合物、组合物及其用途
WO1994028892A1 (en) Inhibitor for rejection accompanying organ transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160509

R150 Certificate of patent or registration of utility model

Ref document number: 5934647

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250